---
title: "Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294234662.md"
description: "Entera Bio (ENTX) shares rebounded after announcing an oversubscribed $275 million private placement to fund its EB613 Phase 3 osteoporosis program through 2030. Investors weighed the capital boost against dilution risks from issuing ~123 million shares at $2.04. BVF Partners leads the round, gaining board seats. Despite broader market declines, ENTX rose 0.31% to $3.27, trading above its 20-day SMA but showing overbought RSI signals. Analysts maintain a Buy consensus with a $9 price target ahead of Aug 11 earnings."
datetime: "2026-07-29T16:03:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294234662.md)
  - [en](https://longbridge.com/en/news/294234662.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294234662.md)
generator: "portal-rs"
---

# Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk

**Entera Bio Ltd.** (NASDAQ:ENTX) shares traded higher Wednesday after the company announced an oversubscribed private placement expected to raise approximately $275 million.

Entera Bio shares are up in recent trading, rebounding from an initial decline. Investors weighed the significant capital injection against dilution concerns from the large securities issuance.

The stock moved upward even as the broader market faced headwinds, with the S&P 500 falling 0.9% and the health care sector gaining 0.2%.

 **• Entera Bio stock is trading at elevated levels. What’s next for ENTX stock?**

## **What Is Driving ENTX Stock?**

Entera expects the financing to extend its cash runway into 2030 and fund EB613’s Phase 3 program through a planned FDA application.

EB613 is Entera Bio’s investigational once-daily oral PTH(1-34) peptide tablet for osteoporosis, designed as a bone-building treatment.

Entera will sell approximately 122.96 million ordinary shares and pre-funded warrants covering up to 11.84 million shares. The company priced the ordinary shares at $2.04 each and the warrants at $2.04 minus their nominal exercise price.

Existing investor **BVF Partners L.P.** is leading the financing, alongside **Longitude Capital, Vivo Capital, TCGX, RA Capital Management, Perceptive Advisors** and other investors.

After closing, BVF will also gain the right to designate two directors to Entera’s board, subject to applicable requirements.

## **ENTX Technical Outlook: Momentum, RSI and Key Levels**

With Entera Bio’s stock price at $3.20, it is significantly above its 20-day simple moving average (SMA) of $2.07, indicating bullish momentum in the short term.

The Relative Strength Index (RSI) reached 70.83, signaling overbought conditions and increasing the risk of a pullback if investors take profits.

This overbought condition indicates that the stock may be stretched to the upside, and traders should watch for potential corrections.

-   **Key Resistance**: $4.20 — This level is significant, as it marks the 52-week high and could attract selling pressure if reached again.
-   **Key Support**: $2.07 — This level aligns with the 20-day SMA, providing a potential floor for the stock if it continues to decline.

## **ENTX Earnings Preview and Analyst Price Target**

Entera Bio is expected to report earnings on Aug. 11. Analysts project a loss of eight cents per share, wider than the six cents loss previously reported, with no revenue expected. 

The stock carries a Buy consensus rating and an average price target of $9. **HC Wainwright** maintained its Buy rating on April 27 but lowered its price target to $9.

**ENTX Stock Price Activity:** Entera Bio shares were up 0.31% at $3.27 at the time of publication on Wednesday, according to Benzinga Pro data.

 **Read Also: Boston Scientific Cuts Forecast on Product Slowdown and Competition** 

*Photo: Shutterstock*

### Related Stocks

- [ENTX.US](https://longbridge.com/en/quote/ENTX.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [BSX.US](https://longbridge.com/en/quote/BSX.US.md)

## Related News & Research

- [Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 286.7%](https://longbridge.com/en/news/295783160.md)
- [Entera Bio (NASDAQ:ENTX) Announces Earnings Results](https://longbridge.com/en/news/295289580.md)
- [BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment](https://longbridge.com/en/news/296376333.md)
- [Entera Bio prices USD 275 million private placement at USD 2.04 per share](https://longbridge.com/en/news/293933037.md)
- [Entera Bio Q2 FY26 net loss widens to $7.3 million; R&D expenses more than double to $3.2 million](https://longbridge.com/en/news/295272747.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**